Risk factors, biochemical markers, and genetic polymorphisms in early coronary artery disease

Arquivos Brasileiros de Cardiologia

Volumn 80, Issue 4, 2003, Pages 388-395

  Izar, Maria Cristina ^a   Helfenstein Fonseca, Francisco Antonio ^a   Miki Ihara, Sílvia Saiuli ^a   Kasinski, Nelson ^a   Sang, Won Han ^a   Lanzarini Lopes, Ieda Edite ^a   De Almeida Pinto, Leonor Do Espírito Santo ^a   Miranda Relvas, Waldir Gabriel ^a   Lourenço, Daisy ^a   Tufik, Sérgio ^a   De Paola, Angelo Amato Vincenzo ^a   Camargo Carvalho, Antonio Carlos ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Coronary artery disease; Genetic polymorphisms; Risk factors

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOCHEMICAL MARKER; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN C; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; LIPID;

ADULT; ALLELE; ANAMNESIS; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SMOKING; THROMBOSIS; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; GENETIC POLYMORPHISM; GENETICS; HEMOSTASIS; MIDDLE AGED;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HEMOSTASIS; HUMANS; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 4444229394     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2003000400003     Document Type: Article

References (44)

1. Brasil, Ministério da Saúde. Sistema de Informações sobre Mortalidade - SIM. Brasil, 2000. Em: http//www.datasus.gov.br. Accessed August 11, 2001.
2. Wilson PW, D'Agostini RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
5. Reaven GM. Insulin resistance and its consequences: non-insulin dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus. Philadelphia: Lippincott-Raven Publishers, 1996: 509-19.
6. Reichl D, Miller NE. Pathophysiology of reverse cholesterol transport: insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis 1989; 9: 785-97.
7. Brown VW, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972; 46: 375-82.
8. Bruns GA, Karathanasis SK, Breslow JL. Human apolipoprotein AI-CIII gene complex is located in chromosome 11. Arteriosclerosis 1984; 4: 97-104.
9. Karathanasis SK. Apolipoprotein multigene family: tandem organization of human apolipoprotein A-I, C-III and A-IV genes. Proc Nat Acad Sci USA 1985; 82: 6374-8.
10. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE. DNA polymorphism adjacent to the human apolipoprotein AI gene: relation to hypertriglyceridemia. Lancet 1983; 1: 444-6.
11. Rees A, Stocks J, Sharpe CR, et al. Deoxyribonucleic acid polymorphism in the apolipoprotein AI-CIII gene cluster: association with hypertriglyceridemia. J Clin Invest 1985; 76: 1090-5.
12. Paulweber BW, Friedl W, Krempler F, Humphries SE, Sandhofer F. Genetic variation in the apolipoprotein A-I-C-III-A-IV gene cluster and coronary heart disease. Atherosclerosis 1988; 73: 125-33.
13. Ordovas JM, Civeira F, Genest J, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus: relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1991; 87: 75-86.
14. Dallingha-Thie GM, Lind-Sibenius Trip MV, Rotter JI, et al. Complex genetic contribution of the apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. J Clin Invest 1997; 99: 953-61.
15. 2° Consenso Brasileiro sobre Dislipidemias. Arq Bras Cardiol 1996; 67: 1-16
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
17. Clauss A. Quick method to estimate fibrinogen by a functional clotting assay. Acta Haematol 1957; 17: 237-46.
18. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulski AG. Hyperlipidemia in coronary artery disease: II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544-68.
19. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338: 1650-6
20. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002; 21: 213-37.
21. Faergeman O. Methods for detecting coronary disease: epidemiology and clinical management. Acta Physiol Scand 2002; 176: 161-5
22. Schmermund A, Mohlenkamp S, Stang A, et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J 2002; 144: 212-8
23. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at eight years. Eur Heart J 1998; 19(Suppl A): A2-A11.
24. Stamler J, Dyer AR, Shekelle RB, Neaton J, Stamler R. Relationship of baseline major risk factors to coronary and all-cause mortality and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology 1993; 82: 191-222.
25. Malerbi DA, Franco LS. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr. The Brazilian Cooperative Group on the Study of Diabetes Prevalence. Diabetes Care 1992; 15: 1509-16.
26. McGill HC Jr, McMahan A, Malcom GT, Oalmann MC, Strong JP, for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vasc Biol 1997; 17: 95-106.
27. Blann AD, Steele RH, McClooum CN. The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 1997;85:433-8.
28. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284: 311-8.
29. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994b; 35: 871-82.
30. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993; 88: 2180-9.
31. Genest JJ, Bard JM, Fruchart JC, Ordovas JM, Wilson PF, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 1991; 90: 149-57.
32. Sandholzer C, Saha N, Kark JD, et al. Apo (a) isoforma predicts risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12: 1214-26.
33. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA 1998; 279: 1477-82.
34. Sato S, Nakamura M, Iida M, et al. Plasma fibrinogen and coronary heart disease in urban Japanese. Am J Epidemiol 2000; 152: 420-3.
35. Scarabin PY, Aillaud MF, Amouyel P, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 males participants in a prospective study of myocardial infarction - the PRIME study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80: 749-56.
36. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Circulation 1995; 91: 284-90.
37. Tataru M-C, Heinrich J, Junker R, et al. D-Dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999; 20: 1493-502.
38. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517-22.
39. Davies MJ. Stability and instability: the two faces of coronary atherosclerosis. The Paul Dudley White Lecture, 1995. Circulation 1996; 94: 2013-20.
40. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo, JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities. Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
41. Juo SHH, Wyszynski DF, Beaty TH, Huang HY, Wilson JEB. Mild association between the A/G polymorphism in the promoter of the apolipoprotein AI gene and apolipoprotein AI levels: a meta-analysis. Am J Med Genet 1999; 82: 235-41.
42. Reguero JR, Cubero GI, Batalla A, Alvarez V, Hevia S, Coto E. Apolipoprotein AI gene polymorphisms and risk of early onset coronary disease. Cardiology 1998; 90: 231-5.
43. Dallinga-Thie GM, Bu X-D, Lin-Sibenius Trip MV, et al. Apolipoprotein AI-CIII-AIV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoprotein B and CIII. J Lipid Res 1996; 37: 1-13.
44. houlders CC, Harry PJ, Lagrost L, et al. Variation at the AI/CIII/AIV gene complex is associated with elevated plasma levels of Apo CIII. Atherosclerosis 1991; 87: 239-47.